205503-41-9Relevant academic research and scientific papers
Selective Pneumocystis carinii dihydrofolate reductase inhibitors: Design, synthesis, and biological evaluation of new 2,4-diamino-5- substituted-furo[2,3-d]pyrimidines
Gangjee, Aleem,Guo, Xin,Queener, Sherry F.,Cody, Vivian,Galitsky, Nikolai,Luft, Joe R.,Pangborn, Walter
, p. 1263 - 1271 (1998)
Nonclassical antifolates, 2,4-diamino-5-substituted-furo[2,3- d]pyrimidines 3-12 with bridge region variations of C8-S9, C8-N9, and C8-O9 and 1-naphthyl, 2-naphthyl, 2-phenoxyphenyl, 4-phenoxyphenyl, and 2-biphenyl side chains were synthesized as phenyl r
Isotope-effect profiles in the oxidative N-demethylation of N,N-dimethylanilines catalysed by lignin peroxidase and a chemical model
Baciocchi, Enrico,Gerini, M. Francesca,Lanzalunga, Osvaldo,Lapi, Andrea,Lo Piparo, Maria Grazia,Mancinelli, Simona
, p. 2305 - 2310 (2007/10/03)
Lignin peroxidase catalyses the oxidative N-demethylation of ring-substituted N,N-dimethylanilines by an electron-transfer mechanism whereby an anilinium radical cation is formed which is then deprotonated by the enzyme. Information on the nature of the basic centre which deprotonates the radical cation has been obtained by determining the KDIE profile (plot of kH/kD vs. the pKa of the aniline radical cations) for a number of ring-substituted N,N- bis(dideuteriomethyl)-anilines. From the bell-shaped curve it has been estimated that the pKa of the proton-abstracting base is about 7. Interestingly, almost the same value has been obtained when the same type of study has been carried out using a water-soluble model compound: 5,10,15,20-tetraphenyl-21H,23H-porphine-p,p′,p″, p?-tetrasulfonic acid iron(III) chloride. This is a strong indication that the radical cation is deprotonated by the same species in the enzymatic and in the chemical reactions. It is suggested that this species is the reduced iron-oxo complex.
Pyrrolo pyrimidine and furo pyrimidine derivatives
-
, (2008/06/13)
This invention discloses compounds, and pharmaceutically acceptable salts thereof, useful in therapeutically and/or prophylactically treating patients with an illness. Such illnesses include cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii in immunocompromised patients. The compounds themselves, methods of making these compounds, and methods of using these compounds are all disclosed. More specifically, the compounds include pyrrolo?2,3-d!pyrimidines and furo?2,3-d!pyrimides and derivatives thereof.
